In August 2021, the International Vaccine Institute (IVI) has announced that the first participant received Bharat Biotech's Chikungunya vaccine candidate (BBV87) in a Phase 2/3 clinical trial in which country?
In August 2021, the International Vaccine Institute (IVI) has announced that the first participant received Bharat Biotech's Chikungunya vaccine candidate (BBV87) in a Phase 2/3 clinical trial in which country? Correct Answer Costa Rica
The correct answer is Costa Rica.
- The International Vaccine Institute (IVI) has announced that the first participant received Bharat Biotech's Chikungunya vaccine candidate (BBV87) in a Phase 2/3 clinical trial in Costa Rica.
- The development is the start of a multi-country study led by IVI in partnership with Bharat Biotech and funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
- The announcement furthers CEPI's USD 3.5bn plan, launched in March 2021, to tackle future epidemics and pandemics, which includes advancing vaccine candidates against known high-risk pathogens such as Chikungunya.
- CEPI first partnered with IVI and Bharat Biotech in June 2020, providing up to USD 14.1 million for vaccine manufacturing and clinical development of the BBV87 vaccine candidate.
মোঃ আরিফুল ইসলাম
Feb 20, 2025